drugset / Trial / NCT02054052

Intrapleural Bevacizumab Injection for Malignant Effusion in Lung Cancer

NCT02054052 ↗

Phase 2 Completed 22 enrolled Haihong Yang, MD, Pricipal investigator
NaSingle-groupOpen-labelTreatment

Summary

Malignant pleural or pericardial effusion is common in lung cancer, and intrapleural drugs injection is important in the treatment. Non- cytotoxic drugs include those with a sclerosing effect that produces pleurodesis, which is easy to cause severe chest pain despite of no influence on the following chemotherapy. Tumor angiogenesis is important in producing MPE. Bevacizumab has been administrated locally in treating optic nerve sickness successfully by anti-VEGF mechanism. So we hypothesize that intrapleural bevacizumab is also effective in treating MPE.

Timeline

Start
2014-01
Primary completion
2019-03
Completion
2019-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab Monoclonal antibody 100 mg Other